- Home
- FRME vs SLNO Comparison
FRME vs SLNO Comparison
Compare FRME & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRME | SLNO |
|---|---|---|
| Founded | 1893 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | FRME | SLNO |
|---|---|---|
| Price | $37.34 | $46.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $47.33 | ★ $110.90 |
| AVG Volume (30 Days) | 286.7K | ★ 1.3M |
| Earning Date | 01-29-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.84% | N/A |
| EPS Growth | ★ 32.99 | N/A |
| EPS | ★ 4.00 | N/A |
| Revenue | ★ $649,589,000.00 | $98,675,000.00 |
| Revenue This Year | $13.81 | N/A |
| Revenue Next Year | $14.43 | $155.86 |
| P/E Ratio | $9.36 | ★ N/A |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $33.13 | $41.50 |
| 52 Week High | $45.62 | $90.32 |
Technical Indicators
Market Signals| Indicator | FRME | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 44.88 | 38.10 |
| Support Level | $38.06 | $45.07 |
| Resistance Level | $38.96 | $49.75 |
| Average True Range (ATR) | 0.59 | 2.00 |
| MACD | -0.20 | -0.12 |
| Stochastic Oscillator | 21.36 | 15.17 |
Price Performance
Historical ComparisonAbout FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.